Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.57B P/E - EPS this Y -21.40% Ern Qtrly Grth -
Income -1.33B Forward P/E 25.38 EPS next Y 18.60% 50D Avg Chg 5.00%
Sales 2.56B PEG 2.05 EPS past 5Y 8.58% 200D Avg Chg -5.00%
Dividend N/A Price/Book 1.22 EPS next 5Y 17.80% 52W High Chg -30.00%
Recommedations 2.30 Quick Ratio 4.25 Shares Outstanding 22.79M 52W Low Chg 17.00%
Insider Own 15.66% ROA 2.11% Shares Float 19.31M Beta 0.95
Inst Own 89.17% ROE -17.41% Shares Shorted/Prior 1.35M/0.94M Price 403.75
Gross Margin 54.17% Profit Margin -51.73% Avg. Volume 242,608 Target Price 381.83
Oper. Margin 15.74% Earnings Date Oct 24 Volume 225,812 Change -0.87%
About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories, Inc. News
08:47 AM At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
11/29/24 Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?
11/29/24 Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
11/24/24 Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory
11/21/24 Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference
11/13/24 What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?
11/04/24 Interpreting Bio-Rad (BIO) International Revenue Trends
11/02/24 Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
11/01/24 Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (vs US$3.65 in 3Q 2023)
10/31/24 Q3 2024 Bio Rad Laboratories Inc Earnings Call
10/31/24 Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference
10/31/24 BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
10/31/24 Bio-Rad Laboratories Inc (BIO) Q3 2024 Earnings Call Highlights: Strong Clinical Diagnostics ...
10/30/24 Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates
10/30/24 Bio-Rad: Q3 Earnings Snapshot
10/30/24 Bio-Rad Reports Third-Quarter 2024 Financial Results
10/29/24 What to Expect From These 3 MedTech Stocks This Earnings Season
10/25/24 Shareholders in Bio-Rad Laboratories (NYSE:BIO) have lost 58%, as stock drops 4.6% this past week
10/23/24 Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
10/23/24 FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?